Krishna is an Entrepreneur-in-Residence on the Frazier Life Sciences team and an experienced clinical development executive with a track record of pipeline advancement and drug approvals across therapeutics areas.
Krishna joined Frazier in February 2017 as part of the Hawkeye Therapeutics team, a search company focused on in-licensing and developing high-quality assets from pharmaceutical companies.
Krishna previously served as Chief Medical Officer at Raptor Pharmaceuticals, a company focused on rare diseases, until its acquisition by Horizon Pharmaceuticals in 2016 for $800M. In that role, he oversaw clinical development, regulatory affairs, pharmacovigilance and medical affairs, and was responsible for securing additional drug approvals for Procysbi in nephropathic cystinosis, supporting product launches for Quinsair in Cystic Fibrosis, and advancing the pipeline in other rare diseases including Huntington’s disease, cystic fibrosis, bronchiectasis and nontuberculous mycobacteria (NTM). Prior to Raptor, Krishna served as Chief Medical Officer at CytomX Therapeutics and directed preclinical development and translational research efforts for the Probody platform in oncology and helped secure partnerships with BMS, Immunogen, and Pfizer. Prior to CytomX, he led clinical development and pharmacovigilance activities at Affymax where he was instrumental in securing FDA approval of peginesatide for the treatment of anemia in patients on dialysis. Krishna also held senior level positions in clinical development at Amgen and was responsible for leading clinical development programs in heart failure, anemia of chronic kidney disease, and diabetes.
Krishna holds a B.A. from Stanford University and an M.D. from the University of Texas Health Science Center, San Antonio. He completed his residency in internal medicine at the University of Colorado followed by a clinical and research fellowship in nephrology at Harvard Medical School at the Brigham and Women’s Hospital and Massachusetts General Hospital. Krishna has co-authored a number of scientific and clinical publications in the areas of genetics and renal disease. He also serves as a member of the board of directors for the National Kidney Foundation, Northern California chapter.